Wednesday, December 14, 2016 4:00:33 PM
Quick Shot Testosterone Update
Antares announced on September 22 that it had completed the QST-005 safety study for QuickShot Testosterone (QST). The conclusion of this supplemental safety study completes the clinical work necessary to begin the NDA submission process. Antares is on track to file an NDA in 4Q, 2016. The press release listed side effects seen in the study which appear to be consistent with testosterone replacement therapy and should satisfy the FDA on safety issues. I am projecting an NDA filing on January 1, 2017. I expect a ten month review which would lead to approval on November 1, 2017 followed by a launch on January 1, 2018. Hopefully, these are conservative estimates.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM